12
Clinical Cornerstone ABDOMINAL ADIPOSITY AND CARDIOMETABOLIC RISK Vol. 8, Supplement 4 The Endocannabinoid System: Body Weight and Metabolic Regulation STEFAN ENGELI, MD, AND JENS JORDAN, MD Franz Volhard Clinical Research Center University Clinic Charit4 Campus Buch Humboldt University of Berlin Berlin, Germany The endocannabinoid system elicits multiple physiologic functions that are not fully understood. Antagonism of cannabinoid type 1 (CB 1) receptors has been the only successful new pharmacologic treatment approach in Phase III studies in obesity in the last 8 years. Whereas antagonism of CB 1 receptors acutely reduces food intake, the long-term effects on weight reduction and metabolic regulation appear to be mediated by stimulation of energy expenditure and by peripheral effects related to liver, skeletal muscle, adipose tissue, and pancreas physiology. For example, in the liver, lipogenic enzymes and fatty acid synthesis are upregulated by endocannabi- noids, and in adipose tissue, antagonism of CB 1 receptors increases secretion of adiponectin. Some studies suggest that endocannabinoid formation is increased in obesity, perhaps because endocannabinoid degradation is decreased. Although many questions remain unanswered at present, the emerging concept of endocannabi- noids as metabolic regulators helps to explain the success of rimonabant (SR141716), an antagonist of CB 1 receptors, currently in Phase III studies. (Clinical Cornerstone. 2006;8[Suppl 4]:$24-$35). Copyright © 2006 Excerpta Medica, Inc. The worldwide increase in the prevalence of obesity and associated metabolic and cardiovascular diseases is a matter of increasing concern as more and more patients require treatment. 1,2 Successful use of nonpharmacolog- ic therapy requires highly motivated patients and dedicat- ed teams of physicians, dietitians, and psychologists, 3 a strategy that is demanding for both patients and health care providers. Because few patients attain long-term weight reduction and weight maintenance with nonphar- macologic therapy, 4 pharmacologic therapy will be used increasingly more often and new pharmacologic treat- ment options are required. 5 7 In many therapeutic areas, the goal of drug development has been to further refine the specificity of drugs and molecular targets. Nevertheless, recognition of the pleiotropic eflects of statins, angiotensin-receptor blockers, or glitazones suggests that the approach to cardiovascular and metabolic risk modification in general may require a complex rather than a highly specific approach, s 10 The same observations may hold true for obesity treat- ment. Body weight reduction through a highly specific mechanism may not provide full metabolic and cardio- vascular benefits. One possible approach is to define tar- gets that lead to improved cardiovascular and metabol- ic risk beyond the effect of weight reduction. The endocannabinoid system (ECS) may be such a target. Indeed, this system elicits multiple physiologic func- tions that are not fully understood. ECS antagonism, however, has been the only successful new pharmaco- logic treatment approach in Phase III obesity studies in the last 8 years. 11q3 This article provides an overview of the biology of the ECS and its involvement in obesity- associated disease. The Endocannabinoid System: A Brief History Exogenous cannabinoids (CBs) contained in hemp (Cannabis sativa) extracts and plant parts have been used for medical and recreational purposes for thou- sands of years. The principal chemical compound, delta9-tetrahydrocannabinol (A9-THC), was identified in 1964.14 The history of the ECS, however, is much more recent (Table). 11 34 The first CB receptor was cloned in 1990,16 and the first endocannabinoid--an endogenous CB receptor ligand--was discovered in 1992.18 The first orally available selective receptor antagonist, rimonabant (SR141716), was described in 1994, 2o and the weight- S24

The endocannabinoid system: Body weight and metabolic regulation

Embed Size (px)

Citation preview

Page 1: The endocannabinoid system: Body weight and metabolic regulation

Clinical Cornerstone • ABDOMINAL ADIPOSITY AND CARDIOMETABOLIC RISK • Vol. 8, Supplement 4

The Endocannabinoid System: Body Weight and Metabolic Regulation STEFAN ENGELI, MD, AND JENS JORDAN, M D Franz Volhard Clinical Research Center University Clinic Charit4 Campus Buch Humboldt University of Berlin Berlin, Germany

The endocannabinoid system elicits multiple physiologic functions that are not fully understood. Antagonism of cannabinoid type 1 (CB 1) receptors has been the only successful new pharmacologic treatment approach in Phase III studies in obesity in the last 8 years. Whereas antagonism of C B 1 receptors acutely reduces food intake, the long-term effects on weight reduction and metabolic regulation appear to be mediated by stimulation of energy expenditure and by peripheral effects related to liver, skeletal muscle, adipose tissue, and pancreas physiology. For example, in the liver, lipogenic enzymes and fatty acid synthesis are upregulated by endocannabi- noids, and in adipose tissue, antagonism of CB 1 receptors increases secretion of adiponectin. Some studies suggest that endocannabinoid formation is increased in obesity, perhaps because endocannabinoid degradation is decreased. Although many questions remain unanswered at present, the emerging concept of endocannabi- noids as metabolic regulators helps to explain the success of rimonabant (SR141716), an antagonist of CB 1 receptors, currently in Phase III studies. (Clinical Cornerstone. 2006;8[Suppl 4]:$24-$35). Copyright © 2006

Excerpta Medica, Inc.

The worldwide increase in the prevalence of obesity and

associated metabolic and cardiovascular diseases is a matter of increasing concern as more and more patients require treatment. 1,2 Successful use of nonpharmacolog-

ic therapy requires highly motivated patients and dedicat- ed teams of physicians, dietitians, and psychologists, 3 a strategy that is demanding for both patients and health

care providers. Because few patients attain long-term weight reduction and weight maintenance with nonphar- macologic therapy, 4 pharmacologic therapy will be used

increasingly more often and new pharmacologic treat- ment options are required. 5 7

In many therapeutic areas, the goal of drug development

has been to further refine the specificity of drugs and molecular targets. Nevertheless, recognition of the pleiotropic eflects of statins, angiotensin-receptor blockers,

or glitazones suggests that the approach to cardiovascular and metabolic risk modification in general may require a complex rather than a highly specific approach, s 10

The same observations may hold true for obesity treat- ment. Body weight reduction through a highly specific mechanism may not provide full metabolic and cardio-

vascular benefits. One possible approach is to define tar-

gets that lead to improved cardiovascular and metabol-

ic risk beyond the effect of weight reduction. The endocannabinoid system (ECS) may be such a target. Indeed, this system elicits multiple physiologic func-

tions that are not fully understood. ECS antagonism, however, has been the only successful new pharmaco- logic treatment approach in Phase III obesity studies in

the last 8 years. 11q3 This article provides an overview of the biology of the ECS and its involvement in obesity- associated disease.

The Endocannabinoid System: A Brief History Exogenous cannabinoids (CBs) contained in hemp

(Cannabis sativa) extracts and plant parts have been used for medical and recreational purposes for thou- sands of years. The principal chemical compound, delta9-tetrahydrocannabinol (A9-THC), was identified in 1964.14 The history of the ECS, however, is much more recent (Table). 11 34 The first CB receptor was cloned in

1990,16 and the first endocannabinoid--an endogenous CB receptor ligand--was discovered in 1992.18 The first

orally available selective receptor antagonist, rimonabant (SR141716), was described in 1994, 2o and the weight-

S24

Page 2: The endocannabinoid system: Body weight and metabolic regulation

Clinical Cornerstone • ABDOMINAL ADIPOSITY AND CARDIOMETABOLIC RISK • Vol. 8, Supplement 4

TABLE. A BRIEF HISTORY OFTHE ENDO- CANNABINOID SYSTEM (ECS)fl 1-34

Year Discovery

1964 A°-THC identified 14

1 9 8 8 High-affnity cannabinoid (CB) binding sites in the brain identified 15

1990/1991 Rat CB 1 receptor clonedl6/human CB1 receptor cloned 17

1992 First endocannabinoid identifed: anandamide is

1 9 9 3 Peripheral CB 2 receptor cloned 1°

1994 First c g 1 antagonist developed: rimonabant 2°

1995 Second endocannabinoid identified: 2-AG 21'22

1996 Specific enzyme for anazldmnide degradation identified: F A A H 23

1 9 9 8 Rimonabant found to reduce body weight 24

1 9 9 9 Knockout (CB 14- ) mouse model engineered 25

2003-2006 Peripheral metabolic effects of the ECS discovered 2641

2 0 0 4 Endocannabinoids found to be neurotransmitters 32

2004 Specific enzyme for anandamide synthesis identified: NAPE-PLD 33

2005/2006 Results of RIO study published 11 13 Activation of the ECS in human obesity described 3°'34

cj cj k -THC = delta -tetrahydrocannabinol: C B 1 = cannabinoid type 1: CB~ = cannabinoid type 2: 2-AG = 2-arachidonoylglycerol: FA~H = fatty acid amide hydrolase: NAPE-PLD = N- acylphosphatidylethanolmnine phospholipase D: RIO = Rimonabant in Obesity.

reducing eflects of this compound in rats were reported for

the first time in 1998. 24 Although several important com-

ponents of the ECS, such as the putative endocannabinoid

membrane transporter, are yet to be discovered, the central

eflects of endocannabinoids have been recognized for cen-

turies. The role of endocannabinoids and their signal trans-

mission for the physiology of addiction, locomotion, pain,

and memory have been intensively studied. 25'32'35'36 More

recent discoveries acknowledge that CB receptors mediate

cardiovascular effects 37 and modulate inflammatory

responses. 3s The study of cannabinoid type 1 (CB1)- mediated eflects was stimulated by the discovery of the

specific inverse agonist/antagonist, rimonabant, 2° and the

development of specially bred mice with the CB 1 gene

deleted, known as CB 1 knockout (CB1 -/-) mice. 25

Endocannabinoid Synthesis and Degradat ion

Endocannabinoids are synthesized from phospholipid

derivatives of arachidonic acid. The 2 most important

endocannabinoids--anandamide (arachidonoylethanol-

amine) and 2-arachidonoylglycerol ( 2 -AG) - - a r e deriv-

ed f rom membrane phospholipids and triglycerides,

respectively. 39 Anandamide is synthesized by N-acyl-

phosphatidylethanolamine phospholipase D (NAPE-PLD)) 3

The process requires the preceding activity of N-acyl-

transferase to supply sufficient quantities of N-arachidonoyl-

phosphatidylethanolamine as a membrane-bound precursor

for NAPE-PLD. 39 Synthesis of 2-AG is a less specific

process. At least in the brain, 2-AG is an important

intermediate in several biochemical pathways and is

present at a concentration that is -200 times higher than

anandamide. 39 Thus, several enzymes not specifically

belonging to the ECS contribute to 2-AG synthesis.

K E Y P O I N T

The 2 most important endocannabinoids

manandamide and 2 -AGmare derived

from membrane phospholipids and

triglycerides, respectively.

One distinctive feature of endocannabinoids is "use-

dependent synthesis." In contrast to classical neurotrans-

mitters, endocannabinoids are not stored in vesicles.

Instead, they are synthesized on demand in response to

acute stimulation. The response is mediated through

increased intracellular calcium concentrations that initi-

ate endocannabinoid synthesis. 39

Endocannabinoid production and degradation occur

rapidly. After synthesis and release, endocannabinoids

are taken up again by a transporter that has not yet been

identified and then enzymatically degraded within the

cells. Anandamide is specifically degraded by fatty acid

amide hydrolase (FAAH). 39 FAAH gene expression has

been demonstrated recently in several human t issues-- in

the central nervous system (CNS) and in peripheral

organs. 34 This observation is indirect evidence for a

broad distribution of endocannabinoids throughout the

body. 2-AG is inactivated by a less specific e n z y m e - -

monoacylglycerol lipase, which is present in

adipocytes-- to facilitate release of nonesterified fatty

acids. 4° Monoacyglycerol lipase was first characterized

as part of the ECS in the mouse brain in 2002. 40

$25

Page 3: The endocannabinoid system: Body weight and metabolic regulation

Clinical Cornerstone • ABDOMINAL ADIPOSITY AND CARDIOMETABOLIC RISK • Vol. 8, Supplement 4

Endocannabinoid Receptors

Endocannabinoids bind to G-protein-coupled receptors, namely the CB 1 and cannabinoid type 2 (CB2) receptors. CB~ receptors represent the single most abundant receptor

type in the mammalian CNS and are found in several brain regions--the olfactory bulb, cerebellum, cortex, hypothal- amus, nucleus accumbens, basal ganglia, and spinal cord. 41

Surprisingly, recent studies revealed that CB 1 receptors are also present in peripheral tissues, such as the gastrointes- tinal tract, liver, adipose tissue, skeletal muscle, testes, uterus, placenta, and bone. 26 28,34,42-44 C B 1 receptors are

expressed on endothelial cells as well, 45 and this may con-

tribute to positive CB 1 signals in whole-organ prepara-

tions. 34 In human and rodent adipose tissue, CB~ expres- sion is stronger in adipocytes than in other cell types, including preadipocytes, suggesting that CB 1 receptors contribute to the phenotype of mature adipocytes. 28'29'34

CB 2 receptors are predominantly expressed on peripheral immune cells, 41 but they recently have also been described in mouse liver .6 and human adipocytes. 47 The role of CB 2

for adipocyte biology and metabolic regulation remains completely unknown at present.

A typical response to CB-receptor activation is inhibi- tion of adenylate cyclase activity, resulting in reduced intracellular cyclic adenosine monophosphate (cAMP)

levels. 41 However, other second messenger systems, such as protein kinases and transcription factors, are involved as well. On the molecular level, retrograde signaling is an important part of endocannabinoid action. 32'39 Retro-

grade signaling refers to the fact that CB1 receptors are located on presynaptic neurons, whereas the activating

endocannabinoids are produced by postsynaptic neurons (Figure 1). 4s Through retrograde signaling, postsynaptic

terminals of specific neurons modulate presynaptic neu-

rotransmitter release via endocannabinoids and CB~ receptors, which inhibits calcium channels and opens potassium channels. Inhibition of neurotransmitter

release by presynaptic CB~ receptors has been shown for acetylcholine, norepinephrine, serotonin, glutamate, and cholecystokinin. In contrast, dopamine release appears to

be enhanced by CB~ receptors in certain parts of the brain. 32'39 The significance of each endocannabinoid sig-

naling pathway, however, needs to be specified in each

organ or cell of interest, and these data are currently missing for most peripheral organs. Whether retrograde signaling also occurs in peripheral tissues (eg, modula-

tion of norepinephrine or acetylcholine release from

autonomic neurons by endocannabinoids produced by

target cells) remains a matter of debate.

Endocannabinoids, Food Intake,

and Body W e i g h t Exogenous CBs and endocannabinoids increase food

intake and promote weight gain in experimental animals through activation of central CB 1 receptors. 49 51 In-

terestingly, food intake can be induced even in animals that have already been fed and by administration of endo-

cannabinoids in brain regions not directly involved in food intake, for example, the nucleus accumbens. 52

Furthermore, endocannabinoid levels in the hypothala-

mus increase with fasting and are rapidly suppressed by feeding. 52 The influence of endocannabinoids on feeding

behavior is attributable, in part, to interactions with the

stomach-derived hormone ghrelin. The orexigenic effects of centrally administered ghrelin were abolished by rimonabant, suggesting that ghrelin acts, at least in part,

by increasing endocannabinoid production in the hypo- thalamus. 53 However, the response of circulating ghrelin

to fasting was also diminished by rimonabant, suggesting that CB 1 receptors are also involved in ghrelin secretion. 54

Overall, these findings clearly demonstrate that endo- cannabinoids have a role in the control of all aspects of food intake, 55 a phenomenon that has been exploited in the medical treatment of cachexia using A9-THC. 56

Consistent with the effects of endocannabinoids on

feeding behavior are the results of studies with CB(/- mice and rimonabant with respect to body weight changes. CB{/- mice are lean and resistant to diet- induced obesity. 57 Body weight and body fat mass of

CB(/- mice are approximately 24% and 60% lower than wildtype (CBI+/+) mice, respectively. The lean phenotype

is associated with changes in the balance between orexi- genic and anorexigenic systems within the CNS. In CB{/- mice, hypothalamic expression of the anorexigenic

gene--corticotropin-releasing hormone--is increased. Expression of the orexigenic gene--cocaine- and amphetamine-related transcript (CART)--is decreased. 29

These findings may explain, in part, the body weight reduction in CB{/- mice. Recent studies also demonstrated that CB~ activation in CB~ +/+ mice increased CART

expression in hypothalamic nuclei and the nucleus accum- bens, again suggesting that CART is a downstream medi- ator of orexigenic endocannabinoid actions. 5s Similar to

genetic inactivation of CB 1 receptors, pharmacologic CB 1

$26

Page 4: The endocannabinoid system: Body weight and metabolic regulation

LZ~S

g~'uo!ss!cu.lad q~,!~ pa~,depv "uop, epe.l~ap pue a~le~,dn Xq pa~,eln~a.~ Xl~,UeU!cuopa.~d s! s.~o~,da~a.~ LB::::) ~p, deuXsa.~d a~,eAp,~e o~,/O,!l!qel!eAe p!ou!qeuue~opu:l "ased!l ap!.~a -~Xl~OUOCU pue (HVV-I) aSelO-~pXq aP!CUe ppe X.~,e} se q~ns sacuXzua Xq u~op Ua~lO.~ q uaq~, pue (j.) .~a~odsue.~, p!ou!qeuue~opua ue Xq Slla~ o~,u! cln Ua~le~, aq o~, ~,q~noq~, a.~e sp!ou!qeuue~opu:l [:)] ,,'~U!leU~!S ape.~o.~,a.~,, se u~ou~ I ssa~o.~d e 'paseala.~ ~u!a q s~a~,~,!cusue.~,o.mau u!e~a~ jo X.~!l!qeqo.~d aq~, sa~npa.~ uop,~e s!qj.'suo.mau sno!.~eA jo SleU!CU.~a~, ~p, deuXsa.~d uo s.~o~,da~a.~ (LB::)) L ad/o, p!ou -!qeuue~ o~, pu!q o~, ~,jal~ ~p, deuXs aq~, sso.~e (u!a~,o.~d ~) su!a~,o.~d ~upads Xq pa~odsue.~, a.~e SleU -!cu.~a~, ~p, deuXs~,sod Xq paseala.~ sp!ou!qeuue~opu:l [B] "(a-m~B aq~, u! (~) Xq pa~,e~!pu!) cus!ueq~acu u~ou~lun ue Xq aue.~qcuacu leUO.mau ~p, deuXs~,sod aq~, cuo.~} paseala.~ Xip!de.~ a.~e uaq~, q~!q~ '(~V-Z:) io.~a~Xl~lXouop!q~e.~e-Z: pue ap!cuepueue 'sp!ou!qeuue~opua aq~, jo q~,oq .~o auo jo s!saq~,uXs aq~, sa~,e I -ncup, s cunple~ .~elnlla~e.~,u ! pa~,eAala 'suo.mau acuos u I "(+ze::)) suo! cunple~ jo xnBu ! ue pue uop, ez!.~e I -odap s~,! sasne~ uo.mau ~p, deuXs~,sod e }o uop, e~,pX:l [V] "sp!°u!qeuue~°PUa Xq ~U!leU~!S ape.~o.Oa~l • I a-m~!-I

uo!:qq!qu

W W IIIIA

+ze::)

as~d!l ap!aaaXl~OUOUa pu~ aS~lOapX q ap!ua~ pp~/'a~-~:l

aa~.aodsu~a~, p!ou!q~uu~opu 3

ao:~da~aa aa:~!uasu~a:~oana N

a~uJ~nl~ ao "v'~'v'9 da~!.!Lusul~d~odnau ~u!u!,a'~uo3 al3!Sa A

do~da3ad p!ou!q~uu~a t~3 D

p!ou!q~uu~aopu3

ms!u~qaam u,~ou>lu n

uoFqq!qul

O O

@

O ®

OO

El

17 ]u~uI~Iddn~ '8 "IOA • )ISIZl 31"IOSVJ.3WOIOZlV3 ONV JJ.ISOdlOV "IVNIWOOSV • ouolsaouaoD lU~!U!lD

Page 5: The endocannabinoid system: Body weight and metabolic regulation

8~:S

-ni~, uo u!lnsu ! jo slaojjo oql ol 0A.II.ISUOS 0JOU, I SlgA~ 00RI, I

osoqo polgO~l-ltmqguom.t~ jo olosnut lglOlO~Is polglOSi "ola

-snm i~lOlO~is u! £1.IA.II.ISUOS u!lnsu ! 1.m~!I £~m SD~ OtkL ~9"~J ~ola~J qla~o~, ~,U.mUOJ

-stm~l jo UO!l~ttuoj oql Y, uploolq £q £IlXed 'S~oldooo~ tflD JO tlO.IllgA.IlOlgtI.I 9.I10tI0~ JO ttlS.ItlO~lgltllg a.tf, OlOa~tuxeqd

£q poqs.m.m~!p £i~,uoJls S~A~ so!Jn.fu! i~a.mDqa pu~ a!io q

-~lom old.tllnm 01 SlIOa IOA.I l tmmnq jo osuodso~ a.tloiq.tj

oql 'o~ouuoqlmcI ~9"stmmnq tuo~j onss!l ~OA!I a!loq~!a u! pol~in~,oMn o~ s~oldoao~ tflD c~'sol£aol~doq osnout

pol~IOS! ut s!soqlu£s p!a~ £11EJ jo 01~ oql pos~o~au! osI~ s~oldoao~ tflD jo uo!l~A!laV "oa.mt _/_tflD jo ~OA!I oql U! pol~In~,O~UA~Op S~A~ (i-os~i£xoq~ea VOD-i£1oa~ ptm os~qlu£s p.ta~ Xlllgj) s.tsoqlu£s op.uoa£iQul Joj £xessoaou

sau~Xzua jo uo!ssaMxa '£IluanbasuoD e9"saua~, a!ua~,od!I jo ~01~in~,a~ xa~ ~ s.~ qa!qA~ 'a I U!O1OM ~,u!pu!q ~aatrequa

pal~In~,a~-IO~als '~ola~j uo!ld!~astm~l aql jo uo~ssaMxa pas~a~aap aql u~o~j sllnsa~ uo!l~inumaa~ p!d!I lsu!~,~ uo.tlaoloM oql 1~ql £Ia~I!I lsou~ s! 1I c~'s.tso~q.tJ pu~ ~OA.q

£11~J JO lUOtttdoloao p Oql lSU.t~ polaOloJd OJOA~ Oatttt _/_I~D 'lSEJltlO9 UI "S~IOOA~ 0I ~OlJ~ s!so~q!J .IOA.I l £lJlgO OlU! podoIOAOp pu~ S~IOOA~ ~ ~olJ~ s!sol~ols ~OA!I S~ pOlUOS

-aM l~ql uo!l~Inumaa~ op!~oa£I~,!~l poanpu! ~,u!pooj l~J -q~,!q 'oa.mt od£1-Pi!A~ jo ~OA!I oql UI ~9"oatrels!so~ u!Insu! ol pol~IO~ £IOSOla s! ptm outo~pu£s a!Ioq~lout oql jo ~I~eut

-ii~q ~ s.t uo.tl.tpuoa OtlZ "s.tl.tl~doq s.tsol~ols a.qoqoaI~UOU jo s!souo~,oql~d oql ol olnq!~luoa £~ut UO!I~A!la~ SD~

~9"f aan~!A u! powlo p o~e S£~A~ql~d ~elnaOlOUt i~oqd!~od pu~ i~luoa pol~!pout-p!ou!q~uu~aopuo i~a!loqlod£q

0ql :i9g aan~!A u! UA~OqS S! SD~ oql JO SlaOJJO Iu~oqd!~od posodoM oql jo £~ututuns V ~'f'u.tluuf'.ts p.tou.tquutma

-opuo jo oauosoM snolmb!qn oql slso~,~,ns osi~ sonss!l

I~oqd!~od 1sour u! VNBm HVVcI jo uo!lnq!~ls!p p~oMs -Op!A~ oRL oe'SlIoa-~l a!l~o~au~d u! ptm s~o~atred oql u! pm~lsuouDp uooq osI~ s~q uotssoMxo ~01doao~-t~tD '£I

-luoao~ £~OA 09~i-f/6~ 9~'A~O[ J0qllgJ S.I onss!l osod!p~ ptm 'Ola -ShUt I~lOlO~Is '~OA!I U! UOtSSOMXO ~01doao~-tflD 'u!~q oql

ql.tA~ po~dutoa lax "s~o~atred ptm 'onss!l osod!p~ 'Olasnut

I~lOlO~Is '~OA!I O~ 'Soloq~!p ?; od£1 s~ qans 's~op~os!p a! -Ioq~lout pol~!aoss~-£1!soqo ~oj oatrel~odut! ~elna!l~d jo sonss!z "£~,olo!s£qd tmumq ol ltlEAOIOJ oq £eU~ sf, u.tpu.tj

oql JO II e lou 'o~oJo~oql :SleUt.ttre u.t polanpuoa uooq OAeq so!pros oql jo lSOlAI "olqeWAe elep poqs!Iqnd A~oj o~e o~oql ptm 'pol~els uooq £IlUOaO~ £1uo seq sp!ou!qeuuea -opuo jo slaojjo a!Ioqelout Ie~oqd!~od oql uo qa~eoso}I

sp!ou!qeuue:)opu:l to

s~,:)aJj:l :)!loq~,aN I~aaqd!aad

"su~uunq

pu~ Sl~UU!U~ u! ~,q~!a~ ,(poq pu~ a~l~,u !

poo} pa~npaa ~,u~q~uouu!a q~,!~ uus!u

-o~,u~ tS:~ ~!~OlO~Uua~qd 'sao~,da~aa

tSD jo uop,~^p,~u! ~p, aua~ o~, a~l!uu!s

.LNIOd A:l)l

pooj jo luopuodopu! 'UO!l~InY, oJ o!IOqUlottt Olulnpottt

'stmY,~o i~oqd!~od u! tus!uoY,~lU~ ~oldoao~-~flD o~ojo~oql ptm 'sp!ou!q~tRmoopuo i~oqd!~od 1~ql s!soqlod£q oql Ol polnq!~lUOO 0A~q SUO!I~A~0Sqo 0S0ql JO II~ '~0AOA~OH "ltmq

-lguottttJ JO SlOOJJo Y,u!onpoJ-lqY,!oa~ oql AJ.tJlgIO O1 stmmnq ptm siam!tin u~ popoou o~e SOl~J UO!l~p!xo Ol~Jlsqns ptm o~nl!puodxo £Y,~ouo uo ms!uoY,~ltm tflD jo SlOOjjo

oql jo so!pnls pol!~lO p o~oIAI 9~'oo.rtu pol~O~l-Olo!qoA ut 1~ql u~ql uo!ldmnsuoo uo~,Xxo I~s~q ut os~o~out JoluoJY, %L~ e posnua luuquuout!J '.IOAOA~Oq 'O9ttt! osoqo

uI 6g,gg'OO.ll-l-I -/-I~D oql U! oJnl!puodxo £Y, Jouo pos~oJau!

jo 0A!l~o!pu! u00q 1ou 0A~q ~J snql (£~lOtU!~oI~o loo~!pu! £q po~ns~otu) o~m!puodxo £~,~ouo ptm 'oml~od

-ttD1 £poq 'UO!lOtttooo I jo SlUOttto~nsl~OIAI "osl~o~ou! osll~ £~ttt oJnl!puodxo £~,Jou~ "oz~glu.t £~Jouo u.t uo!lanpoJ ~ £q

pou!~ldxo £ll~!lJ~d £luo s! tus!uoY,~lU~ tflO ql!A~ UO!lOnp -oJ lq~,!OA~ £poq 1~ql lso~,~,ns s~,u!pu!j ~,u!s!JdJns osOtkL

9~'oo.vtu osoqo pol~OJltm tn. lqY,!OA~ £poq oonpoJ Ol lUO.to.tjjns lOU SgA~ 0Otttt polgOXHtreqguottt.t~ ut o:~elU.t

poq poanpo~ oql 1Eql po[gOAOJ '.IOAOA~Oq 'SlllOttt.tJodxo

~,u!pooJ-~!~d "o~lu! poq ptm lq~,!OA~ £poq pos~O~aop OSI~ ltmq~uotu.u 'oamt luo!a!jop-tn.ldoI osoqo uI "o:~eltn. pooj jo uO.tll~Z.ql~ttuou Ol.tdsop so!pros oql lnoq~,no~l os~o~aop ol po

-puol lqQDA~ £poq '£I~,U!S!J(hns "luou~ll~oxl jo ~IOOA~ ls~J oql ~,u!mp £1uo o~lu! pooj poanpo3 ltmql~uottLt3 loX "lq~,!OA~

£poq U! uo!lanpo3 %8I tm tg. Pollnso3 ~,u!pooj l~J-q~,!q jo s~IOOA~ El ~OlJg s~IOOA~ 9 ~oj ltreqguottLt~ ql.tA~ oattt~ jo

luotulgO~l 09,6~'so.tpms ~oqlo ui 6~'oa.mt _/_t~tD tmql ~o!agoq o~g '~OaOA~Oq 'oamt od£1-PI!A~ ~oplo poJ-~!gd "od£1ouoqd tmoI oql ol solnq!~luoa o~lu! pooj posgo~aop 'oa.mt _/_t flD ~,uno£ uI "pools~opun ssoI s! SD~ oql £q oatmlgq £~,~ouo

uuol-~,uoI jo uo!lgln~,o~ mq 'poq!~asop IIOA~ uooq oagq o~lu! pooj uo sp!ou!qgutmaopuo jo slaojjo olnag OtlZ

09'6g'l-g'gg'gg'9g'l-g'g[ tt'stmumq ptm si~uLttm u! lqf,.tOA~ Apoq ptm o~I~lU.t pooj poanpo~ ltmq~uom.u ql.tA~ tus.mof,~lU~

17 lu~uDIddn~ 'g "IOA • )ISRI :)I'IOSVJ.3WOIO~IV:) ONV JU.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 6: The endocannabinoid system: Body weight and metabolic regulation

6Z~S

saoada)aa tit 3 jo uope^

-p)eu! )!aaua~ ao tus!uo~e:lue )!~OlO)eCu

-aeqd Xq paqs!u!cu!p Al~UOaaS se~ sa!an!u !

le)!cuaq) pue )!loqeaacu aldplncu oa

Slla) aa^!l uecunq jo asuodsaa )poaqB aq. L

J. N lOci X:l)l

"ll~aq aanpoJd ol l~.upuoqaol.tttt u.[ 1Jodsul~J1 UOJlaala

moJj s!saqlufis al~qdsoqd!Jl-,g-au!souap~ jo ?,u!idnoaun

fiq fif, Jaua aled!ss!p Salfiaod!pe u~oJ~t L9"SalKaod!pe

u~oJq u! u~oqs uooq XlluoaoJ seq (i-dDfl) I-u!oloJd

f,u!idnoaun jo uo!l!q!qu! pole!pout-t~tD 'pueq Joqlo oql

uo "oJm!puodxo X~,Jouo 01 XllUea!j!u~,!s olnq!Jluoa lou soop 'o~,eJols X~,Jouo Joj XlU!eUt posn s! qa!q~ 'onss!l

osod!pe ol!q~ leql lunoaae 01u! uo~Iel oq 1ShUt 1! 09'lttlgq

-euouuJ ql.t~ luoutleoJ1 ~tn.Jnp uo.tlanpo~ lq~.to~ jo utsttt

-~qaom ~ s~ uop~p!xo p!a~ all~J pas~a~atn. SlSaY, Y, ns anss!l

asod!p~ u! Y,u!i!jo~d uotssa~dxa auaY, qY, noqllV te'slapom

ll~tt~gre ll~luattq~adxa jo anssp asod!pl~ ptre Jaa!l tn. ~llUaaa~

poq!Jasop uooq seq UO!leA!lae t~t D Xq NaVY jo uo!l!q!qui

99"(Ndl~g ) 0SlgtI.D[ u!oloJd poleA!lae-oleqdsoqdouout

ou!souapP.-,g jo uo!l!q!qu! s! sal£aod!pe pue JOA!I ut

of,~Jols p!d!I soatmquo l~ql ~ql~d f,u!Fuf,!s J~lnllOa

-l~Jlu! ~u!Aj!un V "JOA!I aql u! pall~Jlsuou~ap sl~ 'salAaod!pl~

m s!saqluXs appaaXi~,Pl ol olnqpluoa Xeu~ OSle s~ol

-daaa~ t~t;D "salXaod!pe maf, UJOlS ap!JaaXlf,!J1 ol pah'u!I s! qa!q~ jo Xl.tA.HOlg oql 6~'OutXzuo a!uof, od!l e '(qdq) osed!I u!oloJdod!I jo Xl!A!lae oql poseoJau! solXaod!pe

osnout polelOS! u! uo!leA!lae t~t D c(sf, u!pu!j f,u!luoss!p Xq XllUOOO~ poleqop uooq seq leql onss~ tm ve.s;'solXood!pe

o~nleu~ pole!luo~ojj!p ol uosuedu~oa m uo~sso~dxo

t~tD jo slunou~e alqe~ap!suoa ~oqs smXaod!pea~d tmumq

Jou (SliOa g~P#,4-F~g) solXaod!peoJd FUOla osnou~ Joql!ou se 'solXaod!pe oJmeut jo odXlouoqd oql ol polelOJ

oq ol sJeodde uotssoJdxo t~t D 6~.,~'paleJlSUOtttap seA~

sJoldoaoJ t~t D FJoqd!Jod jo uotssoJdxo qa!q~ u! uo!leI

-n~,oJ a!ioqmout ol polelOJ SliOa lsJ!j oql oJo~ smXaod!pv

• s!souof, od!pe ptm 'uo!lanpoJd ouplolXaod!pe 'of, eJols

p!d!i oauonuu ! Xeut SD3 osod!pe oql jo UO!leA!la V

• soaueqJms!p at

-Ioqmout pole!aosse-Xl!soqo jo luoutOAoJduq IFJOAO ptm

uo!lanpoJ ltI~,!o~ Xpoq ol polelOJ oJout s! 1! Joqloq~ Jo lueqeuouqJ jo slaojjo laoJ!p ol onp s! o~Ieldn osoanI~, Ola

-ShUt poAoJduq Joqloq~ oumuolop plnoqs so!pros oJnlncI

9g'Sllgttt.tttlg poleoJ1 oql u! SlOAOI osoanI~, poolq poAoJduq

ol po~qI XlOSOla se~ ~,u!pu!j OJI!A U! s!qz "o~eldn osoa

t9"uopeln~a.i )!loqe~,atu pue ~,q~!a~ Xpoq u! paAIOAU ! sue~ao uo cua~,sXs p!ou!qeuue)opua aq~, Jo suop)e aApe~,n d "Z~ a-m~!-I

1" a>lmdn as°~nlD 1" uo!~dcunsuo~

$ s!saua~°d!pv 1- uo!~aJ3aS u!~3auod!p v \

aua~°d!7

~_~ { sp!ou!qeuue~opu:l

/ ~I~C')J~IJ

;al

),

$ a>ImU ! pooj 3!uopa H :LUa~SXS 3!qLU!']

"cg, z//,'

4, a>le:~u! pooj 3!:m:~soamo H :snmeFq~odX H

17 luouIoIddn~ 'g "IOA • ~ISIZl 311OSVJ.3WOIOZlV3 ONV JJ.ISOdlOV 1VNIWOOSV • ouolsaouaoD lea!U!lD

Page 7: The endocannabinoid system: Body weight and metabolic regulation

O£S

z9"uo!ss!cu.~ad q:l!M pa:Idep'¢ "A:ffsaqo j o ~u!:l:las aq:l u! SalBoJd p!d!l pue :lq~!aM Apoq J O UOFleln~aJ aq:l u! SalOJ :me:iJodcu! Aeld o:I Jeadde SAeMq~ed S:):I asaq:l j o q:loq 'snq.L "e!~eqd.~adA q ~o UOFlUa^aJd pue UOFPnpoJd pF~e A:~ej paseaJ:~ap j o :paJ:la :lau e o:I ~u!pea I 's/,eMq:led q:loq s:ffq!qu ! (a:~!cu :mo)pou)l ti~:) u! '~a) ~U!leU~!S Jo:l -da:~aJ ti~:) j o UoFldnJs!o "asuodsaJ ~!~eqd.~adAq e o~ spea I uJn:l u! q:~!qM'S'¢:l pue :~ ['cl'a:lHS sa:le^ "FPe (:lq~!J) sncueleq:lodAq aq:l u! sJo:Ida:~aJ ti~:) j o UOFlelnCUFl S "Jo!^eqa q ~u!paa J j o UOFHq!qu ! ue 'Al:manbasuo:~ 'pue sncueleq:lodA q aq:l u! (~'¢-Z:) IOJa:Ml~lAouop!q:~eJe-Z: pue ap!cuepueue j o Sla^a I paseaJ:~ap o:I spea I uFlda I j o UOFleJ:Is!u!cupe snoua~oxa 'aldcuexa JO:l "cUS!lOqe:lacu pue Jo!^eqa q ~u!paa J :pajje Ala^Fle~au Aecu sauocuJoq j o Sla^a I paJa:He asaq. L'uFpauod!pe pue 'uFlda I 'u!lnsu ! ~u!pnpu ! '~u!paa J pue cUS!lOqe:lacu q:HM pa:leposse sauocuJoq j o Sla^a I ecUseld sa:leln~aJ OSle AeMq~ed s!q:l 'scus!ueq:~acu :paJ!pu ! Jo :paJ!p Jaq:ffa q~noJq. L ".,la^!l /~.t~e.. I. J.O a:~uaJJn:~:~o paseaJ:~u! aq:l pue Ja^!l aq:l u! s!saq:luAs pF~e/,:l:leJ o^ou ap j o a:leJ aq:l u! aseaJ:~u! leUOFPUnj e o:I spea I /,eMq:led s!q:l j o UOFlelnCUFl S "(S'¢:1) ase:laq:luAs pF~e/,:l:leJ pue [::::)::::)'¢ 'sacuAzua pa:leposse s:ff pue :~ ['cl'a:lHS Jo:l -:~ej UoFld!J:~sueJ:l aq:l j o uo!ssaJdxa saseaJ:~u! UOFlelnCUFlS Jo:Ida:~aJ ti~:) "cUS!lOqe:le:~ s, ap!cuepueue .~oj. alqlsuodsaJ acu/~zua /~ecu!~d aq:l '(H'¢'¢:1) aSelOJp/~q aPlCUe PF ~e /cl:leJ j.o /CllAFPe paseaJ:~ap cuoJj S:llnsaJ q:~!qM JO Ja:l:lel aq:l 'ap!cuepueue Jo Sla^a I pasea.,l:~U! se IlaM se '(:Ual) .,la^!l atl~ u! Sla^a I Jo:Ida:~aJ (tS::)) [ ad/cl p!ou!qeuue:~ paseaJ:~u! o:I spea I :la!p :leJ-q~!q "¢ "(S::)::I) cua:Is/~s p!ou -!qeuue:~opua aq:l u! uo!:leln~aJ a^!:l!:ladde leJ:lua:~ pue :~!ua~od!l leJaqd!Jad Joj s/~eMq:led Jeln:~alOl, d • ~ aJn~!-I

lUp~lnuJps (~ Xao:l!q!qul (~ L~aD~

lu!paa-I $

SV4,1,

t L-clt3"dS ,[,

aa^!l J(:l:le-I

t u!InSUl $ '~ ~ saP!aa~Xl~!al $

up~auod!pv -I" ~'~ ~ s!saq:luXs pp~ X:n~j o^ou aC] $

t 9v-c1" aP!~pu~uv 1"

L~]D $ ~ aP!uJepueuv $

1'

-D

t LDDVP u~ SV-I $

t L-clt3"dS $

t t

>

~(~) u°P~lnuJps L~3D (~~ (~)I

a~!uJ lno)pou) I L~3::)

17 ]u~uI~Iddn~ '8 "IOA • )ISIZl 31"IOSVJ.3WOIOZlV3 ONV J,J.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 8: The endocannabinoid system: Body weight and metabolic regulation

£~ttt uo.tl~p~Jf, op p.tou.tq~utmaopuo pos~oJaop l~ql slsof,

-~,ns £pms ~no u! sp!ou!q~utmaopuo ~,u!l~ina~!a pos~o~au!

pu~ onss!l osod!p~ m uotssoMxo HVVcI pos~o~aop

UOOA~IOq UO!I~!aOSS~ OSOIa OtlZ 0e'DV-?; ptm op.mmp -treu~ jo sloao I ~,u!l~ina~!a ~oq~,!q p~q soloq~!p ql!A~ sluo!l~d pu~ 'slao.fqns osoqo jo soldut~s onss!l osod!p~

|lgIOaS.IA U.I poseoJau! OSle OJOA~ DV-?; JO S|OAOq f~'sp!ou

-!qeutmaopuo ~,u!lelna~!a jo SlOAOI ~O UOtSSOMxo ~oldoao~

-t~t Duo oauonlju! ou peq sso 1 lq~,!OA~ %g V "dno~, osoqo

oql jo onss!l osod!pe oql u! poanpo~ O~OA~ SlOAOI VNBm

HVVcI pue tflD 'lse~luoa uI ~'(1~ aan~!A) UOUtOA~ UeO I ql!A~ po~edutoa UOUtOA~ osoqo U! poseo~au! O~OA~ SlOAOI

DV-?; ptm op.mtepuetre ~,u!lelna~!a leql punoj OA~

• suecunq pue

SleUJ!Ue asaqo u! pa~A!~:)e aq AeuJ

SD:I aq:~ :~eq:~ ~sa~ns sa!pn~s ~ua~a~l

.LNIOd AzlM

• OA.tl~lnaods sut~ttDJ uotssoMxo

ouo~, tflD u! uts!treqaout £~Olgln~,o~ 5iagqpoo J OA.IIE~OU jo oauols!xo oql snRL "slg~ osoqo poanpu!-lo!p oql u!

po~nsgout lou O~OA~ SlOAOI p!ou!qgutmaopuo Ig~luoa 'dooI

~IagqpooJ OA!lg~,OU g UO Olglnaods s~oqlng osoql q~,noqllV rc'snutglgqlod£q oql u! po~,ugqaun pug u!g~q oql

jo suot~,o~ a.mtglgqlod£~lxo u! posgo~aop SgA~ £1!suop

tflD lgql pOA~OqS Slg~ U! £1!soqo poanpu!-lo!p jo so!pros '~OAOA~OH re,sr'Oa.mt qo/qo jo sn~oln oql u! po~,treqaun

pug slg~ ~o~Ianz osoqo jo onss!l osod!pg oql u! posgo~au! SgA~ UOtSSOMxo OUO~, ~01doao~-tflD 'sp!ou!qgutmaopuo

jo SlOAOI onss!l posgo~au! ql.IA~ ~oqlo~,qL oe'Sm£aod!pg jo

urn!pout o~mlna oql u! DV-?; pug op.mtgpugtre jo lumuoa

oql poanpo~ u!ldoI ql!A~ luoutlgo~L "sol£aod!pg IgUOla osnout u! so!pros £q pouoddns ~oqunj s! s!soqlod£q s!qz

• uo!lanpoM p!ou!qgutmaopuo jo ~01gln~,o~ oa!lg~,ou g oq

£gm u.tldo I snqz ~,9~'sn~oln oql u.t pug u.tg~q oql u.t qloq 'Iguuou 01 SlOAOI p!ou!qgutmaopuo po~olso~ oamt (qo/qo)

osoqo u! u!ldoI jo uo.tlg~ls.tu.rtttpv "(slg~ ~o~Ianz osoqo

pug oamt a!loqg!p) s~oldoao~ u.tldo I iguo.tlatmj ~0 (oa.mt

osoqo) u!ldo I ~oql!o ~IagI ptm osoqo £ilga!louo~, o~e olgp

01 poq!~asop slopout oql jo iig '~OAOA~OH r~,9~'POSgo~au! oJo~ sp.tou.tq~tm~aopuo jo SIOAO I ou!Joln ptm a.m~ I

-~qlod£q qloq '£1!soqo jo slopout luopo~ uI "stmumq ptm

SleUt!ue osoqo u! pOll~A.Ilal~ oq £eUt SD~ oql ll~ql lsof, f, ns

I~S

so.tpnls luoao}I "onss.tl ieJoqd.uod u.t s.tselsooutoq a.qoq

-l~lOU~ ptm uo.tl~InY, o~ lqY,.toa~ £poq u.t pOAIOAU.I S.I SD~ oql

l~ql O0uop.tAO pop.tAOM oa~ 'SUO.tl0OS snOtAOM oql uI

~.X~,{s~qo u{ ~^p,~ea~^ 0

cue~sX S p!ou!qeuue:)opu:l eq~ s I

• s~ea aa)pn z

asaqo u! OA!A u! Sla^a I u!~auod!pe

~u!~eln~a p pa~e^ala pue oa~!^ u! anss!~

asod!pe u! uo!ssaadxa aua~ uD~auod!pe

pasea.t~u! uJs!uo~e:~ue .to:~da~a.t tl] ~

.LNIOd Jk:lM

tc's.tsouoY, od.tp~ jo soY,~ls

£IYeO oql oonpu.t ol luouDJ.mboJ £J~ssooou ~ s.t Y,u.q~uY,.ts

pol~!pout-dlNV 3 u_'uo!l~Jluoauoa dlNV 3 J~InlIOa~JlU! S0SEOJ00p £HEo.Id£I UO.IIEA.IIOE ISD SE 'poloodxo lou st

sp.tou.tq~mt~oopuo jo lOOjjo ogDY, od.tp~oM pol~.tpotu -~ flD

lOO~.tp ~ 'I~d.tou.ud uI "pou.mUolop oq Ol poou '~OAOa~oq

's.tsouoY, od.tp~ JO uo.tl~InY, o~ pol~.tpom-p.tou.tq~utmoopuo

jo sms.ttmqaom 13~xo OtlZ o~'S.tsouof, od.tp~ pol~JOlOa3~

~,u!lso~,~,ns 'sol£aod!p~oJd I~UOla osnout u! uo!l~inut

-naa~ p.td.q pol~inm.tls osi~ '0I?;-FIH 'ptmQq JoldoaoJ flD

a!loqlu£s V 69"gd lg 'u!oloJd ~,u!pu!q p!a~ £111gJ oql pu~ u!laouod!p~ s~ qans 'souo~, Jo~I~eut ol£aod!p~ jo uots

-sa~dxa ptm uo!l~inumaa~ op!Joa£i~,!J1 ~,u!pnlau ! 'sol£a -od!p~oJd I7-£i£ osnout jo s!souo~,od!p~ pol~Joloaa~ m

POllnsoJ op.mt~pu~u~ £q uo!l~a!la~ L}IVdd 0L'OUtoJpu£s a!IOq~loUt ql!A~ Sluo!l~d u! SlOAOI u!laouod!p~ os~oJau! 01

ueaoqs uaaq osI~ s~q UO.tl~a.tl0~ L}Igdd 69 "s£~ss~ UO.tl~a -.IlalgStllgI1 U.I op.m~ptretm £q UO.IllgA.Ilalg (L}IVdd) ~um~,

~01daaa~ pal~A!la~-~ol~aJ!IOM au~os~xo~ad pal~lsuouDp

s~,u!pu!j luaaa~ asn~aaq 's!s£I~U~ pal!map ~ spaau

£I~ala sp!ou!q~uu~aopua pu~ u!laauod!p~ UaaA~laq

d!qsuo!l~ia~ atlZ oe'aua~, u!laauod!p~ aql jo uo~ssa~dxa

pal!q!qu! sptm~,!I tflD ql!A~ sal£aod!p~ i~uoi a asnou~

jo uo.tl~inm.tls '£i~,u!p~oaav c9"sol£aod.tp~ UA~O~q U.t pu~

S~Sl~ ~a~Ianz asaqo m OmA U! SlOAOI u!laauod!p~ ~u.tllq -na~a pal~Aala pu~ O~I!A U! anss!l asod!p~ m uo~ssaMxa

ouof, u.tlaouod.tp~ pos~oJau.t tus.mof,~lu~ JoldoaoJ ~flD

s9"slopott~ ll~ttLml~

u! ls~oI 1~ 'o~m!puodxo X~,~ouo 01 ~01nq!~luoa ~InaOlOU~

lu~l~odtu.t u~ snql s.t I-dDfl jo uo~ssa~dxa pas~a~auI

17 luouDIddn~ 'g "IOA • )ISRI }I'IOSVJ.3WOIOZlV} ONV JJ.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 9: The endocannabinoid system: Body weight and metabolic regulation

ZES

-l13A.IlO13JOAO oq Aeu~ SDH OtlZ "soF, ueqa a.qoqelou~ pom.ta -osse ptm u!e~, lq~,!aA~ alou~o3d suo!lae p!ou!qmmeaopua

ie3aqd!3ad ptm Ie31uaa qloH "aatmls!sa3 u!insu! pue uo!l -eum~eUu ! a.m~alsAs ~,u!lou~o3d Aqa3aql 'sauplolAaod!pe

3aqlo aauanlJU ! pue uo!lanpo3d u!laauod!pe u!e31s -a3 Xeu~ sp!ou!qmttmaopua 'anss!l asod!pe uI "alasnu~

IglOlO~Is u! lsgo I lg 'o~Igldn osoanlf, polg!pou~-u!lnsu! pug UO!lglntunaag p!d!l omlnm!lS Agttt sp!ou!qmmgaopuo 'sonss.tl [e.~oqd!.~od uI "SX~A~ttl~d tn.loJq8, ptm tn.ldo I ql!~

uo!la~alu! q~,noJql 1J~d u! 'a:gelu! pooj amlnm!ls sp!ou -.tqm~tmaopua 'u.m~q oql uI "sonss.U l~oqd.uod sno~A U.t ptm u!~Jq oql m. posso3dxo s! u~olsAs ORL "uo!mp~Jf, op ptm s!soql -uAs p.tou.tqmumaopuo u.t pOAIOAU.I SOUtAZUO a.tj.taods ptm

's~ol~odsue~l p.tou.tqeuueaopuo 's~oldoao~ p.tou.tqeutma

-opuo a!j!aods 'sp!ou!qmmeaopuo jo sls!suoa SDH ottL

SNOISnlDNOD

• uo!l~ttu!juoa lmuompodxo spoou s!soqlodAq

s!ql mq :uo!l!sods!p ouo~d-Al!soqo tm ol olnqpluoa plnoa

SDH oql mql os cL'AI!soqo jo luomdoloaop oql u! AIJ~O A.tOA S~)'~ oql jo uo.uelnF, oJsA p ol p~ol OSle £~u~ sosnea a!louo~, ~,u!Apopuf] Lz'Allq~,!IS AlUO poseo~au! peq lq~,!OA~ Apoq Seo~OqA~ 'luoso~d Apeo~Ie O~OA~ Al!A!lae HVVH poseo~aop ptm SlOAOI p!ou!qmttmaopuo poseo~au! '~,u!pooj

lej-qF,.tq jo s~Iooea f ~olje :lo.tp mj-qF,.tq e poj oam~ jo ~oa!i oql u! pol~odo~ SeA~ ~,u!pu!J J~ImqS V "Al!soqo u~ ~naao

t,~'uo!ss!tuaad q~!M pa~depv "uacuoM lesnedouauu~sod uea I snsaa^ $0"0 > d. "~sa~ ~ ~uapn~ S aq~ q~!~ pauuao~ad se~ uos!aeduuo:~ dnoa D "uo!ssaadxa (HQdVD) aseuaSoaphqap a~eqdsoqd-~-aphqapleaa:Mi8 hq paz!leUUaOU ,(Shy ) s~!un haea~!qae u! ua^!8 s! uo!ssaadxa auaD "(O pue D) uauuo~ uea I aq~ q~!~ paaeduuo:~ uauuoM asaqo aq~ u! 'Xla^!~:~adsaa '%65 pue %p[ ~q aa~o I aaa~ VNOUU (H~d) aSel°aP~q apluue ppe ~ej pue VNOUU (tsD) t ad~ P!°u!q euue:~ '~lleU°!~!PPV "(8 pue V) uauuo~ uea I aq~ q~!~ paaeduuo:~ uauuoM asaqo aq~ u! '~1 -a^!~:~adsaa 'aaqS!q %Z$ pue %$~ aaa~ (DV-Z/I) IOaa:~lSl~ouop!q:~eae-Z/I pue ([V3~] au!uuel°ueq~a -i~ouop!q:~eae) ap!uuepueue jo Sla^a I 8u!~eln:~a p 'uauuo~ asaqo aq~ u I "pau!e~qo aaa~ sa!sdo!q anss!~ asod!pe snoaue~n:~qns pue salduues poolq 'uauuo~ lesnedouauu~sod asaqo 0Z pue uea I 0Z jo ~pn~s leUO!~:~as-ssoa:~ e u I "~!saqo ueuunq u! uua~s~s p!ou!qeuue:mpua aq~ jo uo!~e^!~:~eaa^ O

asaqo uea 3 asaqo uea 3

-- - 0"0

- s'z

c~ >

-0"s --o c] I

- S'L >

• 17 a.mS!d

---0

- 0E N

- 017 "-o

- 09 I > C

- 08

0"0t 00t (3 D

asaqo uea7 asaqo uea 3

0 ~-- -0

-0t

- 0Z

I,O

3 O

3

> t

3 O

z 3 I'--

±

0~ ,

17 ]uouIoIddn~ 'g "IOA • ~ISIZl 31"IOSVJ.3WOIOZlV3 ONV JJ.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 10: The endocannabinoid system: Body weight and metabolic regulation

EES

"g0fI-86EI :gI I'g00g "lsa,uq tql D f "~(l!saqo paonpu! -la!p ol samq!~luoo pug s~.saqlu£s pD13 £1113.i sal13[nui~.ls s.~oldaoa.~ (I)~tO o!ledaq le uo!leA!lOe p!ou!qeuueoopu~ "Ie la 'd aaq°ed 'IN olI!alada(I '(I ueuIe!~H-!aso "LE

"kgI-fg1:6E'.g00E "saqo f #q "ao.mi (qo)daq/(qo)daq u! a-'tmdn asoonI~ alosnuI snalos pug uo!lduInsuoo ua~ -~(xo uo 91 k I ~7I ~IS ls!uo~mue .~oldaoa.~ I ~tD p!ou!qeuueo aql .Io sloa.I.I~ "I13 la 'V~) U°Slt.Ak 'dI gaI°uu°o 'qX n!q "9E "17017-I 017:fgg'.6661 "aoua!og "ao.mi lno_-toou_- t aoldaoaa I ~tO u! sale!do jo slooj.ia aAt.lot.ppe paonpa.~ pue sp!ou!qeuueo ol ssauaa!suodsaauFl "Ie la 'D nssoo 'O aPxaaleA 'O luapaq "gE

"kI Iqd-fI Iqd:fg'.866I ".toe aft'/"gILHTI "dS ls!uoSmue p!ou!qeuueo aql Jal.Ie ssoI lqS!aA¢ pug uo~ssaMdns al!ladd V "ie la 'D ze!(I '~I o!qe~v 'D oquIoloD "~TE

"kg-fg:~Tgf'.966I ')dtlJl)N "sap.mIe p!oe-~(nej ~(aolelnpouioanau sapea~ap leql aui~(zua ue jo uo!lez!aaloe -.mqo .mlnoalOlN "i e la 'dS Pla[ILelN 'NO ~Ue!D 'cI~t neAe-~D "rE

"L6-6g :gI E'.%61 "ummuOD salt sdqdo!(t luaqoo!(t "u!eaq u! pue~!i aoldaoaa p!ou!qeuueo snoua~opua alq!ssod V :Ioaao~(I~ -F(ouop!qoeaV-E "Ie la 'V eAce~e-'tns 'S opuoN '~L ean!~ns "~

"06-fg:0g'.g661 "lOOVuuvqd umqoo!( t "s.~oldaoa.~ p!ou!qeuueo ol spu N leql 'ln~ auiueo ui luasaM 'ap!aao~(i~ououi- ~ snoua~opua ue .Io uo!leo -~J!luapI "Ie la 'q snueH 'S leqeqs-ua~t '~I uIelnoqoalN "I~

"~7~-0~:0gf'47661 "lla7 g(/2/d ".~oldaoa.~ p!ou!qeuueo u!e. N aql jo ls!uo~mue aAt.lOalaS pug lualod e 'V91L 117I ~IS • I e la 'IN auiIneaH 'd ql-~e~t 'IN euoui-~eD-!pleu!~I "0E

"g9-I9:g9f'f66I ')JtIII)N • sp!ou!qeuueo .~oI .~oldaoa.~ ie.~aqd!.~ad e jo uo!lez!.~al -oeaeqo aelnoalOlN "IN aeeqs-nqv 'qSI seuIOq~L 'S oaunlN "6I

"61761-91761 :g gE'.E661 "ao ua!og ".~oldaoa.~ p!ou!qeuueo aql ol spu N leql luam!lsuoo u!eaq e jo aam -orals pug uo!lelos I "ie la 'V aanaa~t 'q snueH 'VAk aUeAa(I "8 I

"~TfI-6E1:6LE'.I66I T maqoo!(t "s!lsal u! passaMxa osle s! qo!qA¢ aoldaoaa p!ou!qeuueo ueuinq e jo ~u!uolo .mlnoalOlN "Ie la 'D 1-mSSeA 'O nea-~alIOlN 'IND P-~e-~aD "kI

"~9g-I 9g:9~f'0661 ')dtIII)N "VN(I O pauop aql .Io uo~ssaMxa ieuo!loun~ pug .~oldaoa.~ p!ou!qeuueo e jo aanlonals "Ie la 'fin u!alsuA¢oa~t 'fS l!eI°q 'Vq epnslelN "9I

"f 19-g09 :~7f'.8861 "l°°Vm'wqd 1°I~ "u!e-N le.~ u! .~oldaoa.~ p!ou!qeuueo e jo uo!lez!aaloeaeqo pug uo!leu.mIaala(I • Ie la 'HIN uosuqof 'III Vd z:~esL(I 'YAk aUeAa(I "gI

"L1791-9179I :98'1796I "oog maqD m V [ "qs~.qs13q jo luanl~.lsuoo aM.lo13 u13 jo s~.saqlu£s ie!laed pug 'aamonals 'uo!leIos I "~I uieInoqoaIN 'X !UOeD "17I

" g L L-I 9L:g6g'900g "VI~ VF "Ie!al Paiioaluoo paz.uuopuea V :eo!aauiV qlaoN-OI~I "slua!led asaqo ao lqo~t.aA~aaAO HI. saolo13J -'{six o!ioqmauio!paeo pue lqo~!aA¢ UO 'aa--toolq aoldaoaa i-p!ou!qeuueo e 'lueqeuoui!a jo loo.i.i~ d "ie la 'INH !leuiqsaH 'fq auuoav 'Xd aa£uns-!d "fI

"17fIg-IgIg:fgf'.g00E "PaN f l'~'u~ N "e.Kuap -!d!Is£ p ql!A¢ slua!led lqo~!aACaaAO u! saoloe.I --ts!a o!ioqmaui uo lueqeuoui!a jo sloo.i.H "dnoa D £PmS sp!d!q-£l!saqo u! lueqeuoui!} I aql aoI "1 uigalsg.fs 'V ~(el°D 'dr saadsaG "gI

"L6fI-68fI :g9f'g00E "laotw7 • £pms adoan~d-OI}I aql uio~.I aouauadxa aeaX- I :slua!led lq~I.aA,',.IaAO UI. s.IoloeJ ~st..I .~elnoseAo!p.~eo pug uo!lonpa.~ lq~!aA¢ UO 9ILHTI}IS aa-'toolq .~oldaoa.~ I-p!ou!qeuueo aql jo sloa.I.I~ "[e la 'fV uaaq°s 'INV uauess~.}[ 'dq Iced UeA "I I

"0L~- 09PE :~Tg :gO0; "sa~aqv!(1 "sls!uo~e .~oldaoa.~ palea~.loe-.~ole.~oj~.lo.~d auios~xo.~ad .Io salo.~ o!lnade.~aq~L "Of 1-~eqon-~d '~t slams "0I

"I17~-gflT:lTI'.g00E "suaj.md~(H Io.~qdaN tqdo ..t..ttl~ • saa_-toolq aoldaoaa-u!sualo!o~ue jo slooI.Ia o!doalo!ald pue '-mlnoseao~.P-~eo 'aa~.sual-~a&(q~.luv "V emIa~.S el ap 'O emIa~.S "6

Z98I-gggI :9~7'.g00E "lo!p.wD llOD mV [ "s!s~(Ieue uo!ssaJSaJ-maui V ;uo~.lonpaJ Ioxalsaloqo puo£aq l~..Iaua~{ :sm.lels jo sloo.i.ia o!doalo!ald "Ie la 'N !aeAcqsaqelN '~t ql.uuS 'Dr uosu!qoR "8

"170I-I6:17f'g00E "mV qlaoN U!lD lOaaluaoals*)D • ~(l!saqo .~o.I sa!de.~aql ieo!~olooeui.~eqd "lNq ueldeN "L

"f6 I-g81 :g'. g00g "loovuuvqd oS~2A ddtl~) "slua~e ieo!~olooeui.mqd auios .Io loeduiI :~o%Io!s~qd .~elnoseAo!p -aeo pue ~(l!saqo "V ~elquIaZL 'S luaaed-aqma~t 'dr mdeqD "9

"099-f~79:f'.g00E "s'5'n.~G '5~aut3 tqdo 1.~ad2c3 "sau!Iad!d Ieo!lnaoeui:mqd ol suis!ueqoaui ieo!~OlO!q [aAOtI ~ui.~ui.q :~(l!saqo ~oI s~mp ~u!~aauI?t "DAk sam(ell 'qlN e!aaaoD "g

"0kEg00(IO "gOOE ",ta~[ Is@ as~2q~2fl) G atw.,po D "salaqe!paM ql!A¢ sllnpe aoI suo!luaA.~alu! sso I lqo'a!aA¢ Ieo!~olooeui.~eqd -uou uiaal-o~uoq "I e lo 'V IlaUaAV 'X °~ueqz 'qS s~.M°N "17

"0gfI-flTf1:1717f'.100g "Pal~ f l'?U3 N "aoueaalol asoonI °~ paa!edui! ql!A¢ sloa.fqns o~UOuie alglso.I!I u! Sao~Ueqo £q sm!ilaui salaqe!p g ad£1 jo uo!luaAaa d "Ie la 'Dr uoss-'t!a~d 'f uioalspu!q 'f olqai.KuonL "~7

"6LOE-17LOE:g9I'g00E "PaI~ tualtq qo.~ V "sau!lap!no ~ qlleaH jo salnl~.lsu I [euo~.le N luaJ~no jo 1.~oddns u! aouapt.A~ :~SI..I qlleaq pue 'aoua.~a.guno.~!o lS!eA¢ 'xapu! sseuI ~(po~t "15 sso~I '~Ld -'taz:muizleN 'I uassuef "E

ZLgI-L98I :E9I'.EOOE "Pal~ tualtq qo.~ V "aouauadxa uieqo~u.mIe~d aq~ L :~s~.~ ~elnoseAo~.p~eo jo slueu.rm~alap se £1~.saqo pug lqo~t.aA~aaAO "I13 la 'q UeA~.lln S '~{}[ om.lsoo~V,(I 'Akd uosl~.Ak "1

S3DN3~I3d3~I

• sa~ueq) )!loqe~acu pa~eposse

pue u!e~ ~q~!a~ a~ocuoad suo!~)e p!ou!q

-euue)opua le.~aqd!aad pue lea~ua) q~o~]

.LNIOd A:I)I

"slu0.tlgd osoqo ptrg lq~.t0~JOAO

m sJolagJ ~ls.H ~lnaSgAO.tp~a ptrg a.qoqgl0ttt 0AOJdttn

O1 qagoMdg lUOmlgO~l ~,u!sguoM g s! ms!uo~,mug ~Ol

-doao~ t~D 1~ql lso~,~,ns £i~uo~ls so!pros Iea!u!Ia III oseqd

'ssoIoql~OAON "ouop oq ol summo~ qa~eoso~ qanm 'slem

-~tre u! pug IOAOI ~glnlIOa oql lg UOA~ "stmmnq u! po!pms

IIOA~ uooq 1OU seq SD~ oql JO X~,OlO!SXqd oql 'poopuI

"sosoqlodXq osoql JO II~ l~oddns ol po~!nbo~ o~e so~

-pros ~oqund "poseo~aop s! uo!lepe~,op p!ou!qemmaopuo

osneaoq Xlo~i! I 1sam 'stmmnq ptm slem!ue osoqo u! po

17 luomolddn~ 'g "IOA • ~ISRI 31"IOSVJ.3WOIOZlV3 ONV JJ.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 11: The endocannabinoid system: Body weight and metabolic regulation

PES

"ffI I-0fI I :gI I'.g00g • lsa,uq tql D f "s!saua~od!I jo uo!lelnpouI p!ou!qeu -ueaopu~ :lq~noql ~o~ po%I "cI~ 11eAeaO 'HV ueuIlqa!q "E9

"00I-fk:kg'900g 'tab .*oopu3 "ooueleq ~(°~ouo pue uo!lelno%a ou!aoopuo u! tuols~(s p!ou!qeuueoopuo oql .Io oloa o~mo~aotuo oq~L "Ie lo '(I m°O 'D oueo!SaelN 'FI o11oo%d "I 9

"69gI-L9g1:6I'.g00E T (t~EVd "ooueleq ~(o~aouo pug s!s~(iod!i .Io uo!lelno%a oql qo%oaql o&(louoqd ~(l!soqo poonpu!-lo!p oql sosaoaoa lueqeuotu!a ls!uoo%lue aoldoooa

I HO oq£ "ie lo 'IN ououav 'O nolI!ZL-lou!aeH 'O oI!qf "09 "fgfB

-glTf~I:178E:fOOE "lO!S£qd f mV "oorui osoqo poonpu!-lo!p u! 'ls!uo~mue .toldooo.t I~tO e '9ILIH}IS jo loo.i.io ~(l!soqo -!lu V "Ie lo 'O a~ao~p(I 'IN auomv 'O nolI!a~L laU!Ae~I "6g

"EgE-fLE:I 8'. g00E "l°tW°°Pua°'maN "ap.mIep -ueue snoua~opua jo loajja oma~xaao aql u! pOAIOAU ! s T op!ldod ld!aosueal poleloa-ou.~moqdme pue -ou!eoo O • Ie lo 'f ol!qAk-aOAaeH 'IN olI!alodo(I '(I uetue!aH-pso "8g

"8179-0179:8E'.1700E "saqo [ ltq "~(I!A!I!SUOS u!ldo I poouequo pug ~(l!soqo poonpu!-lo!p ol ooums!soa 'ssouueo I ol speo I oo.~ u! lno-'toou-'t aoldoooa p!ou!qeuueo I~tO "I e 10 'O lOUOlN 'O o°~o°~IoO 'O nolI!~£ IOU!AeH "kg

"06I-ggI :g6'E00E :taq£ lOOlnu.wqd "olBodde pue 8m.pooj m. sp!ou!qeuueoopuo pue Iou!qeuueooJp~(qe~lOL "B melnoqoolN 'IN~ £JJo~ "9g

"17fL-6EL:06'.f00E :qnN [ -¢6¢ go~u!leo .Io Ioaluoo o!uopoq pug o!lmsoomoq oql qloq m oloa V :tuols~s p!ou!qeuueo oq£ "D stue!II!Ak 'Vf ploJ~eH "gg

"I9L-LgL :E6'.P00E "alnN f "~8 "°P.~eI°ueql°F(°°I° pue (lueqeuom!~) V9ILI17I}IS 'spunodmoo p!ou!qeuueo omoo~xoaoue ~(q I-°P!ldod ozt!I-uoo%onlo ~ pug u!Ioaxt o~ etuseld.Io uo!lelnpom Ie!lUmOd "I e 10 'INV -'tou!~LON 'qlN eLoluolN '(Id !ueo "17g

"fgg-Ogg:f'eI:'eOOg "lOS~mUmld f.~8 "u!Ioaq~ o.~eleqlo&(qe~lu! jo sloajjo omo~ qxaao aql s-'toolq 9ILI17I}IS ls!uoo%lue aoldoooa I~O p!ou -!qeuueo aq~L "Ie lo 'IN sl!uoqaoN '2,IA saao%B 'VS portaL "fg

"Lgg-0gg:9fI'.E00E "lOOmu2vqd [ ,¢6¢ "io~0o32i o~ i32ouop!qoeae-E 32q o~u!leo jo uo!leInuI!lS :uot.ll~t.yes pug o~ut.pooj 'o~ut.lsl~j o1 uoBelo.[ m snuIeleql -od32q pue u!eaqoao~ o!quI!I lea u! SpAO I p!ou!qeuueo -opu H "I e 10 'd ezzod 'INO stue!II!Ak 'OJ~ tueqs~!N "gg

"0gg-117E:9L'.E00E :wq~/ lO!S'dqd "op.miepueue pug OHJ-6eIIO(I £q poonpu! o~u~.pooi JO st.s£leUe [eUOI.leAJosqo "OJ~ tueqs~t.N 'INO SUlet.llt.3A "[g

"LIf-gIf:ftTI:6661 "(l.*a(I) £,5'OlOOl)uul)qdoqods d

-aOAO soonpu! ap.mIepueu V "&L uIeqN!N 'INO suIe!II!Ak "0g "~gI I-IgI I :~fI'I00g "l°°Vuuvqd f .~t

• sle.[ m. ol~.lodde solelnuIBs snuIeleqlod£q [e~.p~uIo.quoA oql olu! uo!leals!u.mIpe ~p.mIepueu V "V(I aol£e~ 'N !p!qsuIef "617

"0fg-kgg:0I~'I00g "aml~)N "spaeA~oeq lo13 sp!ou!qeuueo :£~olo!qoano N "bAD ueq~neA 'fin o!ls!aqo "817

"Lg I-LL1:9E:900E • lo!~I llaD tuaqools!H "salKood!pe snoaumnoqns pue Im -UOUlO Ueulnq u! 'g~tO pue I ~tO 'sJoldoooJ p!ou!qeuueo oql jo oouoso M "i e 10 'S uuetulnoH-sol~t 'q neo~eOH 'B oqooB "k'e

"ggL-g~'L:ggI'g00g "£'5'°l°.*~lu~°.US12D "JOA~.[ oql m. g~O aoldooo.[ pt.out.qeuueo oql jo o[oa o!uoo%.N[I!lu V "I e 1o 'd °-t°IO-e-t!°x!°~L 'd PaeU°-tD 'IJ uo!Inf "917

Z00E-9661:0I I '.f'OOg "u°!l*)ln°'qD "uo!suolaod£q u! uo!lounl aelnoseA -o!pJeo olelnSoJ sJoldoooJ I-p!ou!qeuueo le 8u!loe sp!ou -!qeuueoopu~ "Ie la '(I ueuIe!KH-pso 'd Jaqoed 'S !e-'tle~ "g17

"6Ll-17Ll:I I'.g00g "Pa/N I~N "saoldaaaa p!ou!qeuuea Xq £1!a!lae lselaoalso pue sso I auoq 'sseui auoq jo uo!leln~a~I "ie la '~II ~!aaD 'f~I JOH UeA 'IV s!apI "H7

"60gI-g0gI :fI I'4700E 7ga,uq U!l D f "uo!l -euImeLIU ! o!uoloo lsu!e~e slooloM uImsas p!ou!qeuueo snouo~opuo oq~ L "Ie lo 'H uueuIaOH 'D °ueo!SaelN 'd eSSelN "f17

"8g-I g:I I'. g00g "P°'tda8 Utah lOIN "£1!I!laaJ aol suo!lea!IduI ! pue aa.mI (qo/qo) 1no -~aou~ u!lda I jo snaaln aql u! uIalSXS p!ou!qeuueaopua aql jo uo!leln~aa-dfl "ie la '~L ou~os!~ '~ ap!a d 'IN auoJ~eaaelA[ "E17

"g0g-I91:17g'.g00E ",tab lOOmm~Jqd "saoldaaaa p!ou!qeuuea jo uo!lea~l!sselo "IIAXX "£~oloaeuIaeqd jo uo!ufl Ieuo!leuaaluI "Ie la 'LL aauuo~ 'd qlae~ 'OV 11alACOH "117

"17E80I-6180I :66'.g00E "saoua!og P*)og fl2N OOad "UOI.113AI.1OI3UI. p!ou!qeuueaopua u! o~u!ledD!laed osed!i op!.io -o£[o~ouotu u~.13~ "[13 lo 'l~q o~.[soq '(I ~oluoch130 'd~L qu~.(I "017

"1788-£L8:17'. £00E "!oso.m~N ,~8 I~2N "o~u~.[ TM -~!s p!ou!qeuueaopua jo a!~o I aelnaalouI aq~ L "(I !IpuIO!d "6f

"I If'-0017:g'.g00E "lOmmmq ,tab fl2N "so!lnodmoql £aolemuIeLlU!-!lue se s~nap poseq-p!ou!qeuue O "ALL u!olN "Sf

"SfI I-0fI 1:817'.g00E • lOm)Uu~)qdo.maN "saoldoooa a!oql pug sp!ou!qeuueoopuo £q uo!leln~oa oanssoM pooi~ "D sounN 'S !e-'tle~ 'd aoqoed "Lf

"Sgg-gg8:0117'. 100g "a'¢nl12N • o~elu! pool o~u!u!elu!etu u! pOAlOAtlI " O.I13 sp!ou!qeuueoopuo palelno%a-u!lda q "Ie lo 'q o~ueAk 'NS n.feaedoD 'A ozaelN !(I "9f

"86fI-f6f1:00I:f00g "V g fl tog PvoV lfl2N oo.¢ d "oon3.~ m. om.[oop luopuodop-oo% sl! pue oouo.tolo.td [oueqlo u~. poA[OAtlI. SI. [ aoldoooa p~.ou~.qeuueo etA o~U~.IeUo~.S p~.om.qeuueoopu~ "I e lo 'f ol~.qA, k-~OA.m H 'f n~.q 'q o~UeA, k "gf

"f~'gE-8 f 8E :17g'. gOOE "salaqv!G • £1~.soqo ueuInq u! uIalS~S p!ou!qeuueoopua ieaaqd!aad oql jo UOt.]l?At.]o v "[17 1o 'IA[ qosnedpI%I 'f a-'tuq.o.~t 'S !P°~u~ "~f

"g0fg-g6Eg:6LE'~'00E "utaqD lO!~I f "s~ouo°~uoo sl! pue op.miepueue o~u!leaouoo ~ (I osed!Ioqdsoqd e jo ttot.ll~zt..IOlOl~ -aeqo aeinooioIN "i e lo 'N !oqnsj~ 'f el~.qs~..[oIN '3, olouIe~O "ff

"~8L-I LL:f:'eOOg "os!G gn-~G ,tab I~)N "uoBel~.oldxo oBnode-[oql sly. pue mols~(s p~.om.qeuuea -opuo oqj~ "1 s!Ilooo-qod oO 'IN oolnI!IJ 'A °z-raiN TO "El

• I 0g gg-961 gg :08E t g00g "luaqD lO!(I [ "os13u~.8 u~.olo~d pol13A~.lo13-dl/~ V 13~.A slooJJO 013~.p~130 pug o!ioqmom ieaoqd!aod pug iealuoo qloq oAeq u!paqo ~ pue sp!ou!qeuue o "I e lo 'VS ponj~ '~ eu!qn H '~t NoN "If "08If-IkIf:I6'900E "q~2laIN l°u!-~o°PU3 u!lD [ "e.mIa°~I ~° -aad~q pue ~l!saqo u! pue sIpo o!leaaoued-~l pue asod!pe jo sppouI u! sp!ou!qeuueoopua jo uo!leIno%as~ p pue uo!l -oun1 'uo!leIno%}I "I e lo 'd °pueIaO 'diN aa!qluoD 'I se!leIN "Of

"I f~-fE~:EI I'f00E • lsa,uq U!l D f "s!souoSod!I Ie.toqd!.tod pug OAI..Ip OlUOo~IXO.IO [e~luoo e~A oOUeleq £~ouo slooj.i13 mols£s p!ou!qeuueo snouo~opuo oq~ L "ie lo 'IN dgqoEL 'D oueo!SaelN '(I clod "6E

"17I 6-806:f9'.f00E • lOm)Uu~)qd lOIN "slioo ol£ood!pe poamlno u! pug slea El/El osoqo jo onss!l osod.rpe u! uo!ssoMxo VN~u 0fchoV soseoaou! 91 k 1171 }IS ls!uoSmue aoldoooa I ~tO p!ou!qeuueo oq~L "Ie 10 'V uo°~ueps~ 'IN oqo~t-~(aeD 'IN p!esuo~t "8E

17 luomolddn~ 'g "IOA • )ISIZl 31"IOSVJ.3WOIOZlV3 ONV J,J.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD

Page 12: The endocannabinoid system: Body weight and metabolic regulation

S£S

op'ol!J~qao!ioF, uo'tmjols :i.mm-3 "£uemJo D 'u.qJo,~ ggI£I '0S "slsf, soqlI.[A,k '(6gI sn~H) JoluoD qaseoso}I i~a.m.qD pseqlo A ztrescI '(IIN '.qof, u3 u~JolS :ol aauapuods~aaoa ssaapp V

"6SL-SSL :6g'.SO0g "saqo 1" ~Lq "(HVVcI) asNoap£q ap.mle PDe ~(11N u! ms!qchom~(iod asuassuu e ql!A~ paleDosse ~(1 -!saqo pue lq~!oACJOA O "Ie lo 'V JaqaaD 'f ualeeAk 'Of ad!s "~/.

"8gg-ggg:gS6:g00g "sa~t tql2"~(t gP°°I alqeleled xoI al!ladde 8U!A!ap u! sp!ou!qeuuea snoua8opua Joj a[oJ V :£1~.saqo £Jela~.p ql~.~ sleJ jo suo~o%J a.mI N -eqlodKqealxa ag!aads u! sxoldaaax (I-~tD) I-p!ou!q euuea jo uo~.lelnS~a-uA¢o(I "[e 1~ 'fd 8u.rN 'Of ll°~.[H 'Vf Pl°JJeH "gL

"0g01-8001:0~'.000~ 7o!(1 llaD 1oI~ "slIaa Iq-f~Lf u! s!sauaSod!pe saanpu! uo!leA!lae ~d~d~l~) "f(I muIalN 'Vq uolloD '~df qasna~l "Ik

"Ig-f1:9'.S00~ • ,ta~t saqo v(l!A!l!suas u!lnsu ! ol uo!leDosse pue uo!lelnSaJ 'uo!laV :u!laauod!pv "~d uaslaqa!~l '~dS uasJapad 'SV uq!q "0k

"I gI-'¢L I :L I S:SOO"d

pub uo!leA!lOe Ieuo!ld!JosueJ1 euIuIeSHVdd p~onpu! ~p.mI -epueu v "Ie lo 'f pueqoSelAI 'S lax!eI!H 'IN elnoqeno~t "69

"099-~$9 :17017'.~00~ "aml*)N "s!sauaSouIaaql OAt.ld~pl3 jo 8u!puels -Japun JNnoalouI e spJeA¢o I "IAI~ ueuIIaSa!ds '~ IIaAcoq "89

"8Sf-9Sf:gf'.900g • sa~t qmal~ uuo H "u!leJS!A pue u!loauod!pe jo uo~ssaadxa saolle pue s!souoSouIaoql sl!q!qu! allooa!p 8u!leuS!s aoldaaaa p!ou!qeuue 3 "f u!alN 'IN aaneqssed 'N zlDcaad "k9

" S"g-S I : I'.SOO"g "q~lal~ llaD "uIs!IoqmauI jo 8u!pumsaapun mapoui ol san D sap!Aoad aSheS ~(~aaua luaDu V :aseupt re.a1 -oad paleA!lae-dlNV "ie la '(I 8u!laeO 'J, aa!nblv '~d~d uqeN "99

"9k9-Ik9:gI'.900g "Pa/N I*gN "s!soaq~ aaA!I jo luauI -leaal aql ao~ ~(Saleals Acau V :uIS!UOSelue aoldaaaa p!ou -!qeuuea I ~dO "I e la 'd PJeUaaD '~d ua!Inf 'd aJalO-eJ!ax!aJ, "$9

"8178-6 fg:98'4700g "a!uqqoo!(t • s!selsoauIoq p!d!i jo saolelnSaa aalSelN :saolaej uo!l -d!aasueal daY,IS "I e la 'd PaeSSOa 'a ~(1aeSaH '(I alaaq~ "179 "990g-LSOE : LE: f'OOE "a~*~D s&laqt~!(I "s~.l~.ledaqoleals a~.[o q -oaleuou jo luauIleaal pue s!sauaSoqled aql ol qaeoadd V • Ie la "I ~(an~-e!OaeD '1"I aezeleS-zapueuaad 'f eu!palAI "f9

17 lu~m~lddns 'g "IOA • )ISIZl 31"IOSVJ.3WOIOZlV3 ONV Jd.ISOdlOV "IVNIWOOSV • ouolsaouaoD lUa!U!lD